Abbott's AFP, CA 125 Cancer Tests Unaffected By Consent Decree
This article was originally published in The Gray Sheet
Executive Summary
Abbott Laboratories' AFP and CA 125 diagnostic cancer tests are among the diagnostic products deemed "medically necessary" by FDA and will continue to be made available under the company's Nov. 2 consent decree with the agency.